ClinConnect ClinConnect Logo
Search / Trial NCT03067675

Triton Reference Database

Launched by TOPCON CORPORATION · Feb 24, 2017

Trial Information

Current as of April 29, 2025

Completed

Keywords

No Known Ocular Pathology

ClinConnect Summary

The objective of this study is to collect OCT measurement data on normal healthy eyes in order to determine the reference limits for Topcon DRI OCT Triton based on the percentile points for 1%, 5%, 95%, and 99%.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria
  • 1. Subjects 18 years of age or older on the date of informed consent
  • 2. Subjects able to understand the written informed consent and willing to participate as evidenced by signing the informed consent
  • 3. Subjects presenting at the site with normal eyes bilaterally (cataracts are acceptable)
  • 4. IOP ≤ 21 mmHg bilaterally
  • 5. BCVA 20/40 or better bilaterally
  • Exclusion Criteria
  • 1. Subjects unable to tolerate ophthalmic imaging
  • 2. Subjects with ocular media not sufficiently clear to obtain acceptable OCT images
  • 3. HFA visual field (24-2 Sita Standard, white on white) result unreliable (based on manufacturer's recommendation), defined as fixation losses \> 20% or false positives \> 33%, or false negatives \> 33%
  • 4. Visual field defects consistent with glaucomatous optic nerve damage based on at least one of the following two findings:
  • 1. On pattern deviation (PD), there exists a cluster of 3 or more points in an expected location of the visual field depressed below the 5% level, at least 1 of which is depressed below the 1% level;
  • 2. Glaucoma hemi-field test "outside normal limits."
  • 5. Narrow angle
  • 6. History of leukemia, dementia or multiple sclerosis
  • 7. Concomitant use of hydroxychloroquine and chloroquine

About Topcon Corporation

Topcon Corporation is a global leader in precision measurement and imaging solutions, specializing in the fields of ophthalmology, optometry, and geospatial technology. With a commitment to advancing healthcare through innovative technologies, Topcon develops cutting-edge diagnostic equipment and software that enhance clinical decision-making and improve patient outcomes. The company actively sponsors clinical trials aimed at evaluating the efficacy and safety of its products, contributing to the advancement of eye care and vision science. Through collaboration with healthcare professionals and research institutions, Topcon continues to drive innovation and support the development of evidence-based practices in the medical field.

Locations

New York, New York, United States

Jamaica, New York, United States

Chicago, Illinois, United States

Anaheim, California, United States

Pasadena, California, United States

Willmar, Minnesota, United States

Patients applied

0 patients applied

Trial Officials

Charles Riesman, MS

Study Chair

Topcon Corporation

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials